NVAXNovavax, Inc.

$2B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+10.0% YoY

Gross Profit

$34M100.0% margin

Operating Income

-$174M-507.2% margin

Net Income

-$185M-538.8% margin

EPS (Diluted)

$-9.99

Cash Flow

Operating Cash Flow

-$185M

Free Cash Flow

-$186M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$208M

Total Liabilities

$376M

Stockholders' Equity

-$168M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$31M	+10.0%
Gross Profit	$34M	$31M	+10.0%
Operating Income	-$174M	-$172M	-1.3%
Net Income	-$185M	-$184M	-0.5%

NVAX FY 2018 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena